Besides pricing, more changes to healthcare are coming. Physicians have more of a say about the drugs they recommend to patients, and they don’t want cherry-picked data; they want ALL the data. Is pharma ready to act with transparency and speed?
The soaring costs of prescription drugs in the United States have become a major concern for millions of Americans. The debate over pharmaceutical pricing has intensified as healthcare expenses continue to rise. One of the key players in this debate is the pharmaceutical industry, often called “Big Pharma.” Big Pharma has consistently argued against price negotiations, claiming it would stifle innovation and limit patient access to cutting-edge treatments. However, there is a growing skepticism among the public and policymakers about the credibility of these arguments.
According to KFF, 80% of voters want lower drug prices. The Inflation Reduction Act was the first step, allowing the government to negotiate drug prices for Medicare. How has the drug industry responded? With contempt for the general public and trying to shift blame.